09.05.2019 08:00:00 CET

Nexstim Plc: New shares have been registered

Company announcement, Helsinki, 9 May 2019 at 9.00 AM

Nexstim Plc: New shares have been registered

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), refers to the Company announcement dated 6 May 2019 regarding Nexstim Plc's directed share issue. As set forth in such announcement, a total of 939,004 new shares of the Company have been registered within the Trade Register today on 9 May 2019.

Pursuant to the registration of the shares issued in the directed issue within the Trade Register, the number of shares in the Company is 35,400,873.

The trading of the new shares will begin approximately on 10 May 2019.


Martin Jamieson, CEO


Further information is available on the website www.nexstim.com or by contacting:

 Martin Jamieson, Chairman and CEO

+44 771 516 3942

Sisu Partners Oy (Certified Adviser)

Jussi Majamaa
+ 358 40 842 4479

Citigate Dewe Rogerson             

David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949 

About Nexstim Plc

Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBTŪ) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim's NBTŪ system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBTŪ system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

 For more information please visit www.nexstim.com